A Phase IV Study to Assess the Impact of the Change of Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With HIV Infection

Inclusion Criteria: * Men and women ≥ 18 years * Confirmed and documented diagnosis of HIV-1 infection * Virological suppression of more than 48 weeks (confirmed with HIV RNA \<50 copies / ml). The determination of the CV of a routine prior analysis of ≤ 12 weeks prior to signature of consent. * ART in stable dual therapy (\> 48 weeks) with DTG + 3TC * Signed informed consent * Negative pregnancy test in urine or blood Exclusion Criteria: * Inability to obtain written informed consent to participate in the study * Pregnant or breastfeeding women or those who intend to become pregnant during the study period and do not undertake to use proven contraceptive methods. * Any suspicion or confirmation of resistance to TAF, 3TC, FTC, DTG or BIC. In case of have a study of baseline resistance mutations prior to the start of ART has to rule out resistance to investigational drugs. * Patients with hypersensitivity to any excipient used with TAF, FTC, DTG or BIC * Any chronic autoimmune or inflammatory disease * Use of immunomodulatory or immunosuppressive agents, including steroids Chronic treatment with aspirin, statins and other anti-inflammatory agents * Any acute infection in the last 2 months * Estimated glomerular filtration rate (TFGe) \<30 mg / ml / m2 measured by any of the formulas available. The determination of the TFGe of a previous routine analysis of ≤ 12 weeks prior to signing the consent is allowed * Contraindication for the use of TAF * Clinical condition of the patient in rapid deterioration or the investigator considers that there is no reasonable hope that the patient will finish the study * Simultaneous participation in another clinical trial or research study that requires the need of treatment with other drugs outside the study or interfere with the visits of the same. * Any situation that, in the opinion of the investigator, may interfere with the patient's ability to meet the treatment schedule and protocol evaluations